Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice

Journal of Clinical Investigation

Volumn 121, Issue 11, 2011, Pages 4268-4280

  Horikawa, Mayuka ^a   Minard Colin, Veronique ^a   Matsushita, Takashi ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD22 ANTIGEN; INTERLEUKIN 10; MB20 11; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL DEPLETION; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CELL SELECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; LYMPHOMA CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY B LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES, REGULATORY; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INTERLEUKIN-10; LYMPHOCYTE DEPLETION; LYMPHOMA, NON-HODGKIN; MACROPHAGE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLY I-C; TOLL-LIKE RECEPTORS;

EID: 80555124922     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI59266     Document Type: Article

References (70)

1. Anderson KC, Bates MP, Slaughenhoupt B, Pinkus G, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63(6):1424-1433. (Pubitemid 14120390)
2. Maloney DG, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15(10):3266-3274. (Pubitemid 27419340)
3. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26(25):3603-3613. (Pubitemid 46844778)
4. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359-7368.
5. Hamaguchi Y, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol. 2005;174(7):4389-4399. (Pubitemid 40396022)
6. McLaughlin P, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-2833. (Pubitemid 28363048)
7. Anolik JH, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003;48(2):455-459. (Pubitemid 36278014)
8. Cartron G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
9. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21):3940-3947. (Pubitemid 46606207)
10. LeBien TW, Tedder TF. B-lymphocytes: How they develop and function. Blood. 2008;112(5):1570-1579.
11. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev. 2008;223:284-299. (Pubitemid 351986191)
12. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol. 2006;176(2):705-710. (Pubitemid 43099663)
13. Bouaziz J-D, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev. 2008;224:201-214.
14. Mauri C, Ehrenstein MR. The 'short' history of regulatory B cells. Trends Immunol. 2008;29(1):34-40.
15. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol. 2008;8(5):391-397. (Pubitemid 351595221)
16. Rieger A, Bar-Or A. B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators. Nat Rev Immunol. 2008;8(6):486-487. (Pubitemid 351733415)
17. + phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28(5):639-650.
18. Matsushita T, Yanaba K, Bouaziz J-D, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008;118(10):3420-3430.
19. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765. (Pubitemid 32368050)
20. Iwata Y, et al. Characterization of a rare IL-10-competent B cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117(2):530-541.
21. hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 2010;32(1):129-140.
22. Uchida J, et al. Mouse CD20 expression and function. Int Immunol. 2004;16(1):119-129. (Pubitemid 38054633)
23. Minard-Colin V, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV. Blood. 2008;112(4):1205-1213.
24. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006;203(3):743-753.
25. Uchida J, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199(12):1659-1669. (Pubitemid 38821999)
26. Hasegawa M, et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol. 2006;169(3):954-966. (Pubitemid 44411958)
27. Yanaba K, Hamaguchi Y, Venturi GM, Steeber DA, St. Clair EW, Tedder TF. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol. 2007;179(2):1369-1380.
28. DiLillo DJ, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol. 2008;180(1):361-371.
29. Xiu Y, et al. B lymphocytes depletion by CD20 monoclonal antibody prevents diabetes in NOD mice despite isotype-specific differences in FcγR effector functions. J Immunol. 2008;180(5):2863-2875.
30. Yanaba K, Bouaziz J-D, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol. 2009;182(12):7459-7472.
31. Matsushita T, Tedder TF. Identifying regulatory B cells (B10 cells) that produce IL-10. Methods Mol Biol. 2010;677:99-111.
32. Dzhagalov I, St. John A, He YW. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood. 2007;109(4):1620-1626. (Pubitemid 46239596)
33. Hock H, et al. Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. Immunity. 2003;18(1):109-120. (Pubitemid 36120692)
34. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 1999;11(1):115-122. (Pubitemid 29359962)
35. Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA. 2005;102(42):15178-15183. (Pubitemid 41513355)
36. Tedder TF, Baras A, Xiu Y. Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol. 2006;28(4):351-364. (Pubitemid 44900574)
37. Cittera E, et al. The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol. 2007;178(10):6616-6623. (Pubitemid 46717446)
38. Heinz S, et al. Species-specific regulation of toll-like receptor 3 genes in men and mice. J Biol Chem. 2003;278(24):21502-21509. (Pubitemid 36792547)
39. Gururajan M, Jacob J, Pulendran B. Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS One. 2007;2(9):e863.
40. Barr TA, Brown S, Ryan G, Zhao J, Gray D. TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. Eur J Immunol. 2007;37(11):3040-3053. (Pubitemid 350131284)
41. Schröder M, Bowie AG. TLR3 in antiviral immunity: key player or bystander? Trends Immunol. 2005;26(9):462-468. (Pubitemid 41139255)
42. Stebbing N, Grantham CA. Anti-viral activity against encephalomyocarditis virus and Semliki Forest virus and acute toxicity of poly I and poly C administered sequentially to mice. Arch Virol. 1976;51(3):199-215.
43. Robinson RA, DeVita VT, Levy HB, Baron S, Hubbard SP, Levine AS. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. J Natl Cancer Inst. 1976;57(3):599-602.
44. Levy HB, et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis. 1975;132(4):434-439.
45. 12U) in healthy volunteers. Antimicrob Agents Chemother. 1993;37(3):429-435.
46. 12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis. 1996;15(7):580-587.
47. Ambrus JL Sr, Chadha KC, Islam A, Akhter S, Ambrus JL Jr. Treatment of viral and neoplastic diseases with double-stranded RNA derivatives and other new agents. Exp Biol Med (Maywood). 2006;231(8):1283-1286. (Pubitemid 44330563)
48. Giantonio BJ, et al. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs. 2001;19(1):89-92. (Pubitemid 32209790)
49. Gowen BB, et al. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol. 2007;178(8):5200-5208. (Pubitemid 46595304)
50. Nicodemus CF, Wang L, Lucas J, Varghese B, Berek JS. Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol. 2010;202(1):608.
51. Byrd JC, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19(8):2153-2164. (Pubitemid 32366969)
52. O'Brien SM, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19(8):2165-2170. (Pubitemid 32366970)
53. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997;89(8):2994-2998. (Pubitemid 27172587)
54. van Ojik HH, et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res. 2003;63(17):5595-5600.
55. Jahrsdorfer B, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol. 2001;69(1):81-88. (Pubitemid 32095121)
56. Friedberg JW, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β-inducible gene expression, without significant toxicity. Blood. 2005;105(2):489-495. (Pubitemid 40070726)
57. Leonard JP, et al. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res. 2007;13(20):6168-6174. (Pubitemid 350075077)
58. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008;27(2):218-224.
59. Heikenwalder M, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med. 2004;10(2):187-192. (Pubitemid 38524890)
60. James SE, et al. Antibody-mediated B cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood. 2009;114(27):5454-5463.
61. Matsushita T, Horikawa M, Iwata Y, Tedder TF. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling EAE initiation and late-phase immunopathogenesis. J Immunol. 2010;185(4):2240-2252.
62. Poe JC, et al. Amplified B lymphocyte CD40 signaling drives regulatory B10 cell expansion in mice. PLoS One. 2011;6(7):e22464.
63. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4(5):627-630. (Pubitemid 28237366)
64. Shah S, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer. 2005;117(4):574-586. (Pubitemid 41504545)
65. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006;66(15):7741-7747. (Pubitemid 44289234)
66. Adachi O, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 1998;9(1):143-150. (Pubitemid 28361303)
67. Poe JC, et al. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol. 2004;5(10):1078-1087. (Pubitemid 41057728)
68. Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol. 1996;157(10):4371-4378. (Pubitemid 126449355)
69. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174(1-2):83-93.
70. + DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol. 2003;33(4):827-833.